Regulatory Oversight of Cell and Gene Therapy Products in Canada. - PubMed - NCBI

Regulatory Oversight of Cell and Gene Therapy Products in Canada. - PubMed - NCBI

Adv Exp Med Biol. 2015;871:49-71. doi: 10.1007/978-3-319-18618-4_3.

Regulatory Oversight of Cell and Gene Therapy Products in Canada.

Ridgway A1, Agbanyo F2, Wang J3, Rosu-Myles M4.

Author information

Abstract

Health Canada regulates gene therapy products and many cell therapy products as biological drugs under the Canadian Food and Drugs Act and its attendant regulations. Cellular products that meet certain criteria, including minimal manipulation and homologous use, may be subjected to a standards-based approach under the Safety of Human Cells, Tissues and Organs for Transplantation Regulations. The manufacture and clinical testing of cell and gene therapy products (CGTPs) presents many challenges beyond those for protein biologics. Cells cannot be subjected to pathogen removal or inactivation procedures and must frequently be administered shortly after final formulation. Viral vector design and manufacturing control are critically important to overall product quality and linked to safety and efficacy in patients through concerns such as replication competence, vector integration, and vector shedding. In addition, for many CGTPs, the value of nonclinical studies is largely limited to providing proof of concept, and the first meaningful data relating to appropriate dosing, safety parameters, and validity of surrogate or true determinants of efficacy must come from carefully designed clinical trials in patients. Addressing these numerous challenges requires application of various risk mitigation strategies and meeting regulatory expectations specifically adapted to the product types. Regulatory cooperation and harmonisation at an international level are essential for progress in the development and commercialisation of these products. However, particularly in the area of cell therapy, new regulatory paradigms may be needed to harness the benefits of clinical progress in situations where the resources and motivation to pursue a typical drug product approval pathway may be lacking.

KEYWORDS:

CTO Regulations; Health Canada; More than minimally manipulated; Regulation of cell therapy; Regulation of gene therapy; Safety of Human Cells, Tissues and Organs for Transplantation Regulations

PMID:

 

26374212

 

DOI:

 

10.1007/978-3-319-18618-4_3

[PubMed - indexed for MEDLINE]

Public Health Genomics Knowledge Base (v1.2)

Last Posted: Nov-04-2016 2PM

 Gene Therapy expanded expanded

Gene therapy for blistering skin disease appears to enhance healing in clinical trial
Stanford Medicine, November 1, 2016

Gene therapy shows promise for treating Niemann-Pick disease type C1
NIH, October 26, 2016

Making gene therapy available at the point of care
J Harris, PHG Foundation, October 24, 2016

More information on this topic

Last Updated: Nov 04, 2016

• Gene therapy for blistering skin disease appears to enhance healing in clinical trial
  Stanford Medicine, November 1, 2016
• Regulatory Oversight of Cell and Gene Therapy Products in Canada.
  Ridgway Anthony et al. Advances in experimental medicine and biology 2015 87149-71
• Gene therapy shows promise for treating Niemann-Pick disease type C1
  NIH, October 26, 2016
• Making gene therapy available at the point of care
  J Harris, PHG Foundation, October 24, 2016
• Pediatric Sickle Cell Disease - Past Successes and Future Challenges.
  Meier Emily Riehm et al. Pediatric research 2016 Oct
• CLINICAL PROGRESS IN INHERITED RETINAL DEGENERATIONS: GENE THERAPY CLINICAL TRIALS AND ADVANCES IN GENETIC SEQUENCING.
  Hafler Brian P, et al. Retina (Philadelphia, Pa.) 2016 10
• Gene therapy: A new chapter.
  King Anthony et al. Nature 2016 537(7621) S158-9
• Genetic medicines for CF: Hype versus reality.
  Alton Eric W F W et al. Pediatric pulmonology 2016 Oct 51(S44) S5-S17
• Gene therapy: A new chapter
  A King, Nature Outlook, September 2016
• Advances in gene therapy for muscular dystrophies.
  Abdul-Razak Hayder et al. F1000Research 2016 5
• Gene editing meets gene therapy 
  Genomic Education Program, UK, September 2016
• Gene therapy for sickle cell disease passes key preclinical test
  Harvard Gazettte, September 2016
• Gene editing meets gene therapy 
  Genomic Education Program, UK, September 2016
• Gene therapy for sickle cell moves closer as scientists clear unexpected obstacle
  StatNews, September 7, 2016
• Gene therapy 2.0: Will CRISPR make expensive treatment accessible to all?
  D Warmflash, Genetic Literacy Project, August 16, 2016

• Human (44)
• Pathogen (0)

• Human (98)
• Pathogen (0)

• Human (5)
• Pathogen (0)

• Guidelines (1)
• Tier Table (0)
• Synthesis (1)

• Huamn (1)
• Pathogen (0)

Relevant Resources

• Cancer Genomics and Epidemiology Navigator (CGEN)
• Genetics and Genomics Competencies Center (G2C2)
• NIH Genetic Testing Registry
• NIH MedGen Database
• Online Mendelian Inheritance in Man (OMIM)
• PharmGKB